Using Pap tests to find early signs of ovarian cancer
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection
This study is looking at whether the Pap test, usually used to check for cervical cancer, can also help find ovarian cancer earlier by looking for certain proteins in the samples, which could lead to better screening and outcomes for women.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10903975 on NIH RePORTER |
What this research studies
This research investigates the potential of using routine Pap tests, which are typically used for cervical cancer screening, to detect ovarian cancer at an earlier stage. By analyzing the liquid-based samples collected during Pap tests, researchers aim to identify specific proteins shed by ovarian cancer cells. The study employs advanced mass spectrometry techniques to discover these biomarkers, which could lead to a more effective screening tool for ovarian cancer. This approach leverages existing cervical cancer screening methods to enhance early detection of ovarian cancer, potentially improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who undergo routine Pap tests and may be at risk for ovarian cancer.
Not a fit: Patients who have already been diagnosed with advanced ovarian cancer or those who do not undergo Pap tests may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, non-invasive screening method for early detection of ovarian cancer, significantly improving survival rates.
How similar studies have performed: Other research has shown promise in using similar approaches for cancer detection, but this specific application of Pap tests for ovarian cancer biomarkers is relatively novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Skubitz, Amy Patrice — University of Minnesota
- Study coordinator: Skubitz, Amy Patrice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.